Compare INCR & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCR | XTNT |
|---|---|---|
| Founded | 1994 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 47.9M |
| IPO Year | 2021 | 2009 |
| Metric | INCR | XTNT |
|---|---|---|
| Price | $5.01 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.03 |
| AVG Volume (30 Days) | 3.5K | ★ 169.9K |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,337,000.00 |
| Revenue This Year | $200.38 | N/A |
| Revenue Next Year | N/A | $10.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.68 | $0.27 |
| 52 Week High | $6.10 | $0.95 |
| Indicator | INCR | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 40.03 |
| Support Level | $0.81 | $0.32 |
| Resistance Level | $5.58 | $0.49 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 19.51 | 1.54 |
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.